Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell entities : Harpoon therapeutics, inc. save search
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
hpn328 congress cell trial therapeutics response
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-09 (Crawled : 20:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: -2.12%
H: 11.81%
C: 1.86%
hpn328 congress cell trial therapeutics response
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
Published: 2023-04-18 (Crawled : 18:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 1.13%
H: 4.29%
C: -7.14%
hpn217 hpn328 cell preclinical therapeutics results
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
hpn217 therapeutics
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 7.18%
H: 1.33%
C: -3.48%
hpn217 meeting trial therapeutics results phase 1
Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.04%
H: 5.74%
C: 3.61%
tritac therapeutics platform t-cell
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated TumorsHPN328, Harpoon’s fourth TriTAC® T cell engager, enters clinical development
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.13%
H: 17.16%
C: 13.54%
lung cancer cancer t-cell
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
Published: 2021-01-04 (Crawled : 13:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.13%
H: 17.16%
C: 13.54%
lung cancer cancer t-cell treatment
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.